ProCE Banner Activity

HER3 as a Target for ADCs: Rationale and Clinical Evidence


Download this slideset from a live symposium at AACR 2023 to review expert perspectives on structural features and current clinical data with HER3-targeted antibody-drug conjugates, with a focus on use of these agents in breast and lung cancers.

Released: April 19, 2023



Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Funda Meric-Bernstam

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Paolo Tarantino

Paolo Tarantino, MD

Advanced Research Fellow
Harvard Medical School
Department of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.


Daiichi Sankyo, Inc.